BSX - NYSE

Boston Scientific Corporation

BSX·NYSE

$47.69

+0.021%

HealthcareMedical - Devices

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.88B

EPS1.9600

P/E Ratio24.33

Earnings Date07/22/2026

43.67B

Assets

11%

3Y+35.0%

5Y+42.0%

10Y+141.0%

19.20B

Total Liabilities

10%

3Y+29.0%

5Y+24.0%

10Y+69.0%

24.47B

Total Equity

11%

3Y+39.0%

5Y+60.0%

10Y+263.0%

Boston Scientific Corporation Funding & Solvency Profile

BSX · NYSE

Current Assets

Cash & Cash Equivalents2.04B

Net Receivables2.93B

Inventory2.94B

Other Current Assets580.00M

Total Current Assets9 B

Non-Current Assets

Property, Plant & Equipment4.50B

Goodwill & Intangible Assets25.30B

Long-Term Investments842.00M

Other Non-Current Assets559.00M

Total Non-Current Assets6 B

Total Assets

43.67B

Financial Health Analysis

Current Ratio

1.62x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.78x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

3 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

20% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Boston Scientific Corporation Balance Sheet

BSX • NYSE

Boston Scientific Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	2B	414M	865M	928M	1.9B	1.7B	217M	146M	188M	196M	319M	587M	217M	207M	267M	213M	864M	1.6B	1.5B	1.7B
Cash & Short-Term Investments	2B	414M	865M	928M	1.9B	1.7B	217M	146M	188M	196M	319M	587M	217M	207M	267M	213M	864M	1.6B	1.5B	1.7B
Net Receivables	2.9B	2.6B	2.2B	2B	1.8B	1.5B	1.8B	1.6B	1.5B	1.5B	1.3B	1.2B	1.3B	1.2B	1.2B	1.3B	1.4B	1.4B	1.5B	1.4B
Accounts Receivables	2.9B	2.6B	2.2B	2B	1.8B	1.5B	1.8B	1.6B	1.5B	1.5B	1.3B	1.2B	1.3B	1.2B	1.2B	1.3B	1.4B	1.4B	1.5B	1.4B
Inventory	2.9B	2.8B	2.5B	1.9B	1.6B	1.4B	1.6B	1.2B	1.1B	955M	1B	946M	897M	884M	931M	894M	920M	853M	725M	749M
Prepaids	299M	307M	315M	264M	205M	194M	195M	161M	66M	75M	57M	0.0	0.0	0.0	203M	183M	319M	645M	464M	475M
Other Current Assets	580M	831M	622M	731M	799M	1.9B	880M	922M	942M	541M	861M	890M	590M	714M	661M	1B	902M	911M	1.8B	916M
Total Current Assets	8.8B	6.9B	6.5B	5.8B	6.3B	6.7B	4.7B	4B	3.8B	3.2B	3.5B	3.4B	3.2B	3B	3.1B	3.6B	4.1B	5.4B	5.9B	4.9B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.5B	3.7B	3.3B	2.8B	2.7B	2.5B	2.4B	1.8B	1.7B	1.6B	1.5B	1.5B	1.5B	1.6B	1.7B	1.7B	1.7B	1.7B	1.7B	1.7B
Goodwill	18.3B	17.1B	14.4B	12.9B	12B	10B	10.2B	7.9B	7B	6.7B	6.5B	5.9B	5.7B	6B	9.8B	10.2B	12.4B	12.4B	15.1B	14.6B
Intangible Assets	7B	6.7B	6B	5.9B	6.1B	5.9B	7.9B	6.4B	5.8B	5.9B	6.2B	5.6B	6B	6.3B	6.5B	6.3B	6.7B	7.2B	8B	9B
Goodwill & Intangible Assets	25.3B	23.8B	20.4B	18.8B	18.1B	15.9B	18.1B	14.3B	12.8B	12.6B	12.7B	11.5B	11.6B	12.3B	16.2B	16.5B	19.1B	19.7B	23.1B	23.6B
Long-Term Investments	842M	555M	413M	407M	412M	918M	458M	-328M	-191M	-75M	-496M	-447M	-288M	-433M	-458M	-429M	-572M	113M	317M	596M
Tax Assets	3.7B	3.7B	3.8B	3.9B	4.1B	4.2B	4.2B	328M	191M	75M	496M	447M	288M	433M	458M	429M	572M	2.3B	2.3B	583M
Other Non-Current Assets	559M	749M	680M	707M	563M	545M	735M	932M	688M	666M	505M	425M	372M	306M	281M	287M	253M	-2.1B	-2.1B	-346M
Total Non-Current Assets	34.9B	32.5B	28.6B	26.7B	25.9B	24.1B	25.9B	17B	15.2B	14.9B	14.7B	13.4B	13.6B	14.1B	18.2B	18.5B	21.1B	21.6B	25.3B	26.2B
Other Assets	0.0	-1M	0.0	0.0	2M	3M	0.0	-2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	43.7B	39.4B	35.1B	32.5B	32.2B	30.8B	30.6B	21B	19B	18.1B	18.1B	16.8B	16.7B	17.2B	21.3B	22.1B	25.2B	27.1B	31.2B	31.1B
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.1B	1.2B	1.2B	1.1B	1B	671M	807M	349M	530M	447M	211M	264M	248M	243M	206M	186M	212M	400M	261M	635M
Accounts Payable	1.1B	960M	942M	862M	794M	513M	542M	349M	530M	447M	209M	262M	246M	232M	203M	184M	212M	239M	139M	222M
Other Payables	0.0	268M	220M	232M	209M	158M	265M	0.0	0.0	0.0	2M	2M	2M	11M	3M	2M	0.0	161M	122M	413M
Accrued Expenses	1.4B	2.6B	1.1B	830M	2.2B	1.7B	1.6B	630M	591M	572M	504M	512M	488M	452M	466M	436M	472M	438M	498M	466M
Short Term Debt	389M	1.8B	531M	20M	261M	13M	1.4B	2.3B	1.8B	64M	3M	403M	3M	4M	4M	504M	3M	2M	256M	7M
Tax Payables	299M	307M	220M	232M	209M	158M	265M	161M	66M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	161M	122M	0.0
Deferred Revenue	313M	306M	266M	220M	208M	138M	144M	328M	191M	75M	496M	447M	288M	433M	458M	429M	572M	911M	679M	583M
Other Current Liabilities	2.2B	491M	1.9B	1.6B	629M	1.2B	861M	2B	2.7B	2.5B	1.7B	1.7B	1.1B	1.1B	1.1B	1.5B	2.3B	2.4B	2.2B	1.5B
Total Current Liabilities	5.4B	6.4B	4.9B	3.8B	4.3B	3.7B	4.9B	5.3B	5.7B	3.6B	2.4B	2.2B	1.8B	1.8B	1.8B	2.6B	3B	3.2B	3.3B	2.6B
NON-CURRENT LIABILITIES
Long Term Debt	11.5B	8.8B	8.6B	8.9B	8.8B	9.1B	8.6B	4.8B	3.8B	5.4B	5.7B	3.8B	4.2B	4.3B	4.3B	4.9B	5.9B	6.7B	7.9B	8.9B
Deferred Revenue (Non-Current)	369M	329M	311M	289M	276M	257M	1.2B	1.2B	1.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	220M	155M	134M	144M	310M	330M	595M	328M	191M	18M	735M	1.2B	1.6B	1.7B	1.9B	1.6B	1.9B	2.3B	2.3B	2.8B
Other Non-Current Liabilities	1.1B	1.1B	1.3B	1.4B	1.6B	1.7B	2.4B	1.9B	2.4B	2.3B	3B	2.7B	2.6B	2.5B	2B	1.6B	2.1B	1.7B	2.6B	1.5B
Total Non-Current Liabilities	13.8B	11B	10.7B	11.1B	11.3B	11.8B	11.8B	7B	6.4B	7.8B	9.4B	7.7B	8.4B	8.5B	8.1B	8.2B	9.9B	10.7B	12.9B	13.2B
Capital Lease Obligations	571M	527M	395M	352M	395M	408M	282M	6M	1M	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	19.2B	17.4B	15.6B	14.9B	15.6B	15.5B	16.7B	12.3B	12B	11.4B	11.8B	10B	10.2B	10.3B	9.9B	10.8B	12.9B	13.9B	16.1B	15.8B
SHAREHOLDERS' EQUITY
Treasury Stock	-2.3B	-2.3B	-2.3B	-2.3B	-2.3B	-2.3B	-1.7B	-1.7B	-1.7B	-1.7B	-1.7B	-1.7B	-1.6B	-1.1B	-492M	0.0	0.0	0.0	0.0	-334M
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33M	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	17M	17M	17M	17M	17M	17M	16M	16M	16M	19M	16M	16M	16M	15M	15M	15M	15M	15M	15M	15M
Additional Paid-In Capital	21.5B	21.1B	20.6B	20.3B	20B	19.7B	17.6B	17.3B	17.2B	17B	16.9B	16.7B	16.6B	16.4B	16.3B	16.2B	16.1B	15.9B	15.8B	15.8B
Retained Earnings	5.6B	2.7B	819M	-750M	-1.4B	-2.4B	-2.3B	-7B	-8.4B	-8.6B	-8.9B	-8.3B	-8.6B	-8.5B	-4.4B	-4.8B	-3.8B	-2.7B	-693M	-174M
Accumulated Other Comprehensive Income/Loss	-610M	275M	49M	269M	263M	207M	270M	33M	-59M	1M	88M	144M	106M	-33M	-138M	-129M	-43M	-53M	-13M	-1M
Other Total Stockholders' Equity	1M	0.0	1M	0.0	0.0	0.0	0.0	34M	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	24.2B	21.8B	19.3B	17.6B	16.6B	15.3B	13.9B	8.7B	7B	6.7B	6.3B	6.8B	6.5B	6.9B	11.4B	11.3B	12.3B	13.1B	15.1B	15.3B
Total Equity	24.5B	22B	19.5B	17.6B	16.6B	15.3B	13.9B	8.7B	7B	6.7B	6.3B	6.8B	6.5B	6.9B	11.4B	11.3B	12.3B	13.1B	15.1B	15.3B
Minority Interest	239M	233M	248M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	43.7B	39.4B	35.1B	32.5B	32.2B	30.8B	30.6B	21B	19B	18.1B	18.1B	16.8B	16.7B	17.2B	21.3B	22.1B	25.2B	27.1B	31.2B	31.1B
Total Investments	842M	555M	413M	407M	412M	918M	458M	-328M	-191M	-75M	-496M	-447M	-288M	-433M	-458M	-429M	-572M	113M	317M	596M
Total Debt	12.4B	11.1B	9.5B	9.3B	9.5B	9.5B	10.3B	7B	5.6B	5.5B	5.7B	4.3B	4.2B	4.3B	4.3B	5.4B	5.9B	6.7B	8.2B	8.9B
Net Debt	10.4B	10.7B	8.6B	8.4B	7.5B	7.8B	10.1B	6.9B	5.4B	5.3B	5.4B	3.7B	4B	4B	4B	5.2B	5.1B	5.1B	6.7B	7.2B
Shares Outstanding	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039	1,482,442,039

SEC Filings

BSX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	April 30, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 01, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 22, 2026	2026	View Filing
S-4/A S-4/A (Amended) N/A	March 30, 2026	March 30, 2026		View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 28, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 18, 2026	March 18, 2026	2026	View Filing
S-4 S-4 N/A	February 27, 2026	February 27, 2026		View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing

Showing 1 to 10 of 602 filings

Related Guides

Blog Categories

Continue your BSX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.